The US Food and Drug Administration (FDA) has approved the use of Gilead Sciences’ Letairis (ambrisentan) in combination with tadalafil for treatingpulmonary arterial hypertension (PAH) (WHO Group 1) to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability. Letairis is an endothelin receptor antagonist that was first approved in 2007 in the US as monotherapy for PAH to improve exercise ability and delay clinical worsening. Tadalafil is a PDE5 inhibitor that was initially approved for PAH in the US in 2009 to improve exercise ability.

Source: Gilead Sciences